Literature DB >> 31722815

Identification of a Novel RBPMS-ROS1 Fusion in an Adolescent Patient With Microsatellite-instable Advanced Lung Adenocarcinoma Sensitive to Crizotinib: A Case Report.

Yi Zhang1, Min Yu1, Mingming Yuan2, Rongrong Chen2, Mei-Juan Huang3.   

Abstract

Entities:  

Keywords:  MSI-H; NGS; NSCLC; Rare ROS1 fusion; Targeted therapy

Mesh：

Substances：

Year:  2019        PMID： 31722815     DOI： 10.1016/j.cllc.2019.09.003

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  6 in total

Review 1.  Interstitial Deletions Generating Fusion Genes.

Authors:  Ioannis Panagopoulos; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2021 May-Jun       Impact factor: 4.069

2.  Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells.

Authors:  Robert J Rabelo-Fernández; Ginette S Santiago-Sánchez; Rohit K Sharma; Abiel Roche-Lima; Kelvin Carrasquillo Carrion; Ricardo A Noriega Rivera; Blanca I Quiñones-Díaz; Swetha Rajasekaran; Jalal Siddiqui; Wayne Miles; Yasmarie Santana Rivera; Fatima Valiyeva; Pablo E Vivas-Mejia
Journal:  Int J Mol Sci       Date:  2022-01-04       Impact factor: 6.208

Review 3.  ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date.

Authors:  Sébastien Gendarme; Olivier Bylicki; Christos Chouaid; Florian Guisier
Journal:  Curr Oncol       Date:  2022-01-28       Impact factor: 3.677

4.  Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR-ROS1 Fusion.

Authors:  An-Guo Chen; Dong-Sheng Chen; Si Li; Le-le Zhao; Ming-Zhe Xiao
Journal:  Front Oncol       Date:  2022-03-01       Impact factor: 6.244

5.  Prognostic role of alternative splicing events in head and neck squamous cell carcinoma.

Authors:  Yanni Ding; Guang Feng; Min Yang
Journal:  Cancer Cell Int       Date:  2020-05-14       Impact factor: 5.722

Review 6.  Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.

Authors:  Alberto D'Angelo; Navid Sobhani; Robert Chapman; Stefan Bagby; Carlotta Bortoletti; Mirko Traversini; Katia Ferrari; Luca Voltolini; Jacob Darlow; Giandomenico Roviello
Journal:  Cancers (Basel)       Date:  2020-11-06       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.